ACAD Q3'26 Earnings: EPS estimate is 0.20 USD

What happened

ACADIA Pharmaceuticals is scheduled to report its Q3'26 results on November 4 after the market closes, with disclosure expected at 4:05 p.m. ET. The revenue estimate is $332.58 million, and estimated earnings per share, or profit allocated to each share, are $0.20.

Confirmed

Global impact / market context

The report will show whether sales and profit per share meet the stated estimates. A shortfall could raise questions about the company’s ability to turn revenue into profit, while stronger results could support expectations; the article provides no forecast for investor reaction or future performance.

Analyst inference

ACAD is scheduled to report its Q3'26 results after the market closes on November 04. The article gives estimates of 332.58 million USD in revenue and 0.20 USD earnings per share. The results will show whether reported revenue and earnings match those estimates; the article provides no cause for past quarterly changes.

Analyst inference

What to watch

1. Check the November 4 report for actual revenue against the $332.58 million estimate; the result will indicate whether sales matched the stated expectation. Confirmed
2. Compare reported earnings per share with the $0.20 estimate to see whether profit allocated to each share came in above or below expectations. Confirmed
3. If either result misses estimates, investors could reassess expectations for ACADIA’s sales or profit, but the article gives no details about causes or likely follow-up. Analyst inference

Evidence

• Original source link unavailable